8 terminated. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 8 |
| Phase 2 | 2 | Terminated 2 |
Follow Other Solid Tumors: new trials by email Literature Review of Other Solid Tumors trials Research Report on Other Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SGN-MesoC2 in Advanced Solid Tumors PF-08052666 - Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 19 | 2024-08-02 | 2026-07-07 |
| TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors 1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib - Osteosarcoma, Other Solid Tumors | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 20 | 2024-02-15 | 2025-12-12 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) HC-7366 - Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer | Phase 1 | Terminated | HiberCell, Inc. | 35 | 2022-02-23 | 2024-03-08 |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Rovalpituzumab tesirine, Dexamethasone - Malignant Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | AbbVie | 200 | 2016-09-23 | 2020-10-19 |
| A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. LTT462 - Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 65 | 2016-04-15 | 2019-09-19 |
| Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations LXH254, PDR001 - NSCLC, Ovarian Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 142 | 2016-01-18 | 2022-12-21 |
| Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors VELCADE TM (bortezomib) for Injection, or PS-341 - Advanced Non-Small Cell Lung Cancer, Other Solid Tumors | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 46 | 2002-12-01 | 2005-06-24 |
Carcinoma, Non-Small-Cell Lung (4) · Melanoma (3) · Ovarian Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma (1) · Carcinoma, Medullary (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Lung Neoplasms (1) · Mesothelioma (1) · Osteosarcoma (1) · Prostatic Neoplasms (1)
Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms by Site (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Lung Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Respiratory Tract Diseases (4)
Bortezomib (1) · Dexamethasone (1) · Injections (1) · Solutions (1) · WW Domain-Containing Oxidoreductase (1) · naporafenib (1) · pembrolizumab (1) · rovalpituzumab tesirine (1) · spartalizumab (1)
Novartis Pharmaceuticals (2) · AbbVie (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Evopoint Biosciences Inc. (1) · HiberCell, Inc. (1) · Millennium Pharmaceuticals, Inc. (1) · Seagen, a wholly owned subsidiary of Pfizer (1)
United States (5) · Canada (2) · China (2) · Germany (2) · Japan (2) · Spain (2) · Switzerland (2) · France (1) · Italy (1) · Netherlands (1) · Singapore (1) · South Korea (1)
Jose Iglesias, MD (1) · Li Zhang, M.D. (1)
2015 (2)